While the manufacturing of biological tissue meets major societal demands, it also faces significant challenges related to process standardization and scaling up. With these challenges in mind, the French start-up Poietis has developed the Next Generation Bioprinting (NGB) platform to achieve 4D bioprinting of biological tissue in a faster, more affordable and more functional way. The world’s first clinical trial of a bioprinted skin graft will start in 2022 at the University Hospital of Marseille. We spoke with Fabien Guillemot, CEO & Scientific Director of Poietis, and Bruno Brisson, co-founder and Director of Business Development, to find out more about this state-of-the-art technology.
